Day One Biopharmaceuticals Deregisters Securities Following Servier Merger Completion
DAWN has more than doubled off its 52-week low of $5.635.
Summary
Day One Biopharmaceuticals has filed to deregister all unsold securities from its previous S-3 registration statements, following the completion of its merger with Servier Pharmaceuticals LLC.
Key Events · Financing and Capital Events · DAWN
-
Securities Deregistration
Day One Biopharmaceuticals has filed Post-Effective Amendments to its S-3 registration statements to deregister all unsold securities.
-
Merger Completion
The deregistration is a direct result of the successful completion of the merger with Servier Detroit Inc., a subsidiary of Servier Pharmaceuticals LLC, on April 23, 2026.
-
Termination of Offerings
As a wholly-owned subsidiary, Day One has terminated all offerings and sales of securities under its previous registration statements, including an equity distribution agreement for up to $250 million.
Analysis · DAWN · Life Sciences
This POSASR filing confirms the administrative deregistration of all previously registered securities for Day One Biopharmaceuticals. This action is a direct and necessary consequence of the successful completion of Servier's tender offer and subsequent merger, which resulted in Day One becoming a wholly-owned subsidiary. While the merger itself was the primary market-moving event, this filing formally terminates the company's ability to issue or sell securities under its prior registration statements, marking a definitive end to its life as an independent publicly traded entity.
How filings like this one have moved
In the 30 days to Sep 18, 2026, 29.1% of the 1703 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DAWN was trading at $21.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $5.64 to $21.53. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.